Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027497 (nausea)
 23,468 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In a randomised, double-blind, 3-way cross-over trial, the incidence of nausea associated with 2 doxycycline 100 mg formulations (Doryx' and Vibramycin') were compared. The original study cohort comprised 103 healthy male volunteers, with 97 subjects completing the trial. Subjects were randomly allocated to 1 of 3 treatment sequences and received a single dose of Doryx', Vibramycin' or placebo, with a 7-day washout prior to cross-over. At half-hourly intervals, from 0 to 2 h post-dose, subjects completed questionnaires to indicate if they felt nauseous. Data were analysed according to a log-linear method for the analysis of cross-over trials with categorical responses. Seventeen, 29 and 11 subjects experienced nausea with Doryx', Vibramycin' and placebo, respectively. A significantly greater number of volunteers indicated a positive response with Vibramycin' vs Doryx' and vs placebo; the positive response frequency was not significantly different for the Doryx' vs the placebo regimen. Treatment sequence had no significant effect on response, although a marked first-dose effect was noted; the first (vs the second and vs the third) regimen was 1.5-2 times more likely to induce a positive response.
 ...
PMID:Doxycycline tolerance study. Incidence of nausea after doxycycline administration to healthy volunteers: a comparison of 2 formulations (Doryx' vs Vibramycin'). 205 Jan 79

Ninety-eight healthy subjects completed a double-blind, placebo-controlled, multiple-dose cross-over study to compare the incidence of gastrointestinal side effects of Doryx (Parke-Davis, Morris Plains, NJ) capsules (enteric-coated doxycycline hyclate pellets) and Vibramycin (Pfizer, New York, NY) capsules (doxycycline hyclate powder). Doryx produced statistically significantly fewer episodes of nausea, vomiting, stomach of abdominal discomfort, and decreased appetite than did Vibramycin. For every symptom, Vibramycin produced statistically significantly more symptom reports than did placebo. Although Doryx produced significantly more reports of nausea than did placebo, there was no significant difference for the other symptoms. Based on these results, Doryx is superior to Vibramycin when considering the incidence of gastrointestinal side effects.
 ...
PMID:A double-blind, multiple-dose, placebo-controlled, cross-over study to compare the incidence of gastrointestinal complaints in healthy subjects given Doryx R and Vibramycin R. 339 34

Twenty-five men with non-specific urethritis/adnexitis were treated with 200 mg doxycycline monohydrate daily (Vibramycin Tabs) over a period of 10 days. More than half of the patients suffered from chronic inflammations. Microorganisms isolated from urethral secretion and prostate exprimate comprised aerobes, in particular staphylococcus epidermidis and streptococcus faecalis, as well as mycoplasmae, chlamydiae, and anaerobes, mainly bacteroides species and peptostreptococci. Fourty percent of patients additionally had anatomical alterations such as constrictions or strictures of the lower urinary tract. After 10-day therapy with doxycycline 16 out of 24 patients (67%) could be cured and a further six patients (25%) could be improved. Microbiological cure could be achieved in infections with chlamydiae in all cases, in infections with mycoplasmae in 67%, in infections with anaerobes in 80%, and in infections with aerobes in 57% of cases. Overall, the therapeutical success in the investigated patient population with chronic infections which are difficult to treat has therefore to be regarded as excellent. Therapy had to be discontinued in one patient after 3 days due to diarrhoea and nausea. In the other patients toleration of doxycycline was good.
 ...
PMID:[Doxycycline in the treatment of non-specific urethritis and/or prostatitis]. 653 88